Huang Jinke, Lu Mengxiong, Zheng Yijun, Ma Jinxin, Ma Xiangxue, Wang Yitian, Zhang Kunli, Wang Fengyun, Tang Xudong
Department of Gastroenterology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Department of Gastroenterology, Peking University Traditional Chinese Medicine Clinical Medical School (Xiyuan), Beijing, China.
Pain Res Manag. 2021 Dec 15;2021:2752246. doi: 10.1155/2021/2752246. eCollection 2021.
OBJECTIVES: To systematically collate, appraise, and synthesize the current evidence on acupuncture for irritable bowel syndrome (IBS). METHODS: Systematic reviews (SRs)/meta-analyses (MAs) of acupuncture for IBS were searched in eight databases. For quality evaluation of the enrolled studies, Assessment of Multiple Systematic Reviews 2 (AMSTAR-2) was used for methodological quality, Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA) for reporting quality, and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) for evidence quality. RESULTS: Ten studies were included in our review. According to AMSTAR-2, only one study met all the criteria and was rated as high methodological quality, and the rest were rated as low or very low methodological quality. According to the PRISMA checklist, most of the items were fully reported, with the exception of Q5 (protocol and registration), Q8 (search), and Q27 (funding). With the GRADE system, no outcome measure was rated as high quality. CONCLUSIONS: Acupuncture may be a promising therapy for IBS. However, this conclusion must be treated with caution since the quality of SRs/MAs providing evidence is generally low.
目的:系统整理、评估和综合目前关于针灸治疗肠易激综合征(IBS)的证据。 方法:在八个数据库中检索关于针灸治疗IBS的系统评价(SRs)/荟萃分析(MAs)。对于纳入研究的质量评估,采用多重系统评价评估2(AMSTAR-2)评估方法学质量,采用系统评价和荟萃分析的首选报告项目(PRISMA)评估报告质量,采用推荐分级评估、制定和评价(GRADE)评估证据质量。 结果:我们的综述纳入了10项研究。根据AMSTAR-2,只有1项研究符合所有标准,被评为高方法学质量,其余研究被评为低或极低方法学质量。根据PRISMA清单,除了Q5(方案和注册)、Q8(检索)和Q27(资金)外,大多数项目都有完整报告。使用GRADE系统,没有任何结局指标被评为高质量。 结论:针灸可能是一种有前景的IBS治疗方法。然而,由于提供证据的SRs/MAs质量普遍较低,这一结论必须谨慎对待。
Pain Res Manag. 2021-12-15
Ann Palliat Med. 2021-10
Complement Ther Med. 2023-5
Front Public Health. 2022
Front Neurol. 2022-11-18
Front Microbiol. 2024-2-14
Front Cell Infect Microbiol. 2024-1-8
Am J Gastroenterol. 2021-1-1
World J Gastroenterol. 2020-11-7
Evid Based Complement Alternat Med. 2020-10-9
J Can Assoc Gastroenterol. 2019-4
Evid Based Complement Alternat Med. 2019-4-14
J Inflamm Res. 2018-9-21